Cowen analyst, Phil Nadeau, reiterated his Outperform rating on shares of Immunomedics (NASDAQ: IMMU) after the company hosted meetings with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE